Equities

Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.9194
  • Today's Change-0.010 / -1.04%
  • Shares traded544.80k
  • 1 Year change-36.15%
  • Beta1.2894
Data delayed at least 15 minutes, as of Jun 15 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

  • Revenue in USD (TTM)8.00m
  • Net income in USD-23.66m
  • Incorporated1990
  • Employees75.00
  • Location
    Lineage Cell Therapeutics Inc2173 Salk Ave Ste 200CARLSBAD 92008-7354United StatesUSA
  • Phone+1 (510) 521-3390
  • Fax+1 (510) 521-3389
  • Websitehttps://lineagecell.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Galectin Therapeutics Inc0.00-44.78m162.83m14.00---------0.7373-0.73730.00-1.140.00----0.00-177.94-92.08-373.85-121.97-----------10.247.25-------15.26------
Telomir Pharmaceuticals Inc0.00-18.84m162.85m1.00--53.99-----0.6889-0.68890.000.1019------0.00-------------------0.89860.00-------1,430.39------
Capricor Therapeutics Inc27.10m-24.31m164.47m101.00--8.86--6.07-0.8755-0.87550.95740.58340.5246--59.13268,299.50-47.07-54.12-122.20-75.13-----89.72-316.25----0.1548--886.8172.0223.20--45.27--
Alimera Sciences Inc90.22m-22.66m166.07m159.00--4.08--1.84-1.57-1.572.420.77620.89897.113.43567,415.10-21.34-19.08-25.84-27.3786.5286.80-23.74-19.552.51-0.07560.6323--49.1911.62-18.14--236.53--
Rigel Pharmaceuticals Inc120.35m-19.80m167.16m147.00------1.39-0.1135-0.11350.69-0.18060.96230.92414.23818,680.30-15.83-28.82-30.14-47.2693.2297.88-16.45-35.761.17-2.912.13---2.7921.3057.16--68.45--
OptiNose Inc74.02m-30.75m167.29m132.00------2.26-0.2733-0.27330.659-0.87770.74530.87644.74560,772.80-30.91-48.25---98.9588.9886.96-41.47-131.662.17-1.164.16---6.9358.6452.58---27.96--
INmune Bio Inc131.00k-34.50m167.95m11.00--5.25--1,282.08-1.92-1.920.00731.620.0022--0.053511,909.09-57.11-37.82-74.12-41.86-----26,333.59-14,901.03---16.970.2044---58.56---9.92------
Achieve Life Sciences Inc0.00-27.32m168.27m22.00--3.39-----1.29-1.290.001.440.00----0.00-60.15-86.31-109.37-119.59-----------9.330.2574------29.60---14.51--
X4 Pharmaceuticals Inc0.00-128.91m171.30m93.00--165.34-----0.6968-0.69680.000.00620.00----0.00-108.98-61.53-133.20-69.20-------13,288.93----0.9815-------4.93--12.03--
Elite Pharmaceuticals Inc47.32m15.55m171.35m53.0011.033.6910.133.620.01530.01530.04650.04560.74282.244.39892,785.5024.413.5330.624.6145.8246.1032.874.411.191.180.14490.005.8735.57-59.97--83.62--
Lineage Cell Therapeutics Inc8.00m-23.66m173.60m75.00--2.40--21.69-0.1344-0.13440.04550.38360.0722--57.16106,706.70-21.32-19.53-24.82-22.5991.8889.13-295.30-370.88----0.0018---39.1612.3918.22---27.16--
Elevation Oncology Inc0.00-39.35m176.48m29.00--2.20-----1.03-1.030.001.470.00----0.00-42.35---46.30-------------12.500.2889------51.93------
Outlook Therapeutics Inc0.00-159.13m179.52m24.00---------11.48-11.480.00-6.100.00----0.00-281.52-214.69-2,060.72-1,843.48-------3,043.92---26.75--------10.70------
Generation Bio Co9.96m-169.06m182.29m174.00--1.38--18.30-2.56-2.560.15091.990.0278--10.9857,258.62-47.14-36.96-50.75-39.21-----1,696.87-8,879.44----0.00----177.317.34--19.61--
bluebird bio Inc21.73m-91.17m182.67m323.00--0.4615--8.41-0.7446-0.74460.21392.080.0383----67,263.16-16.08-33.02-21.50-37.14-10.0819.44-419.62-4,044.311.42--0.00---1.77-36.7152.62---26.66--
Data as of Jun 15 2024. Currency figures normalised to Lineage Cell Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

42.86%Per cent of shares held by top holders
HolderShares% Held
Broadwood Capital, Inc.as of 31 Mar 202441.67m22.10%
The Vanguard Group, Inc.as of 31 Mar 20248.08m4.28%
BlackRock Fund Advisorsas of 31 Mar 20247.87m4.17%
Logos Global Management LPas of 31 Mar 20246.25m3.32%
Defender Capital LLCas of 31 Mar 20244.97m2.64%
Geode Capital Management LLCas of 31 Mar 20243.25m1.73%
Raffles Capital Management LLCas of 31 Mar 20243.21m1.70%
SSgA Funds Management, Inc.as of 31 Mar 20242.18m1.16%
Prescott General Partners LLCas of 31 Mar 20241.85m0.98%
MAI Capital Management LLCas of 31 Mar 20241.49m0.79%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.